We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other ho... Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. Show more
SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
SARASOTA, Fla., June 26, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (βOragenicsβ or the βCompanyβ), a company focused on developing unique, intranasal pharmaceuticals for the...
SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.11 | -9.5652173913 | 1.15 | 1.185 | 1 | 120521 | 1.08673417 | CS |
4 | -0.46 | -30.6666666667 | 1.5 | 1.5 | 0.97 | 152246 | 1.07536887 | CS |
12 | -0.03 | -2.80373831776 | 1.07 | 3.43 | 0.97 | 144184 | 1.80018914 | CS |
26 | -3.68 | -77.9661016949 | 4.72 | 5.2687 | 0.97 | 115708 | 1.78953271 | CS |
52 | -3.01 | -74.3209876543 | 4.05 | 7.74 | 0.97 | 65470 | 2.03861677 | CS |
156 | -37.42 | -97.2958918357 | 38.46 | 69 | 0.97 | 1000972 | 36.63465641 | CS |
260 | -27.16 | -96.3120567376 | 28.2 | 127.2 | 0.97 | 3034990 | 49.79449707 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions